Kintara TherapeuticsKTRA
Market Cap: $9.82M
About: Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Employees: 2
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
330% more capital invested
Capital invested by funds: $51K [Q1] → $219K (+$168K) [Q2]
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
31% more funds holding
Funds holding: 13 [Q1] → 17 (+4) [Q2]
0.21% more ownership
Funds ownership: 1.27% [Q1] → 1.48% (+0.21%) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for KTRA.
Financial journalist opinion
Based on 4 articles about KTRA published over the past 30 days